Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A
A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A
Doctors at five research hospitals seek male patients with severe Hemophilia A (with Factor VIII Inhibitors) to trial a new product, SB-525, an investigatory gene therapy. This therapy utilizes a harmless virus to deliver a functional copy of the factor VIII (F8) gene to the liver, which may permanently provide sufficient blood coagulation and reduce the need for transfusions.
The treatment requires a single intravenous injection of SB-525 and follow up will involve lab assessments and check-ins over the following year and for up to 3 years.
- Be male and 18 years or older
- Have congenital severe or moderately severe hemophilia A
- Not have participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational product within the last 12 weeks
THE STUDY INVOLVES:
- Screening before the treatment
- A single infusion of the gene therapy drug will be administered
- Monitoring of the patient for a few hours after dosing, with periodic lab assessments required for 3 years.
LOCATIONS AND CONTACTS:
Trials will take place at 13 locations across the United States. See the list of locations.
Contact: Medical Monitor | 510.307.7266 | [email protected]
Or go online: